SUPPLEMENT – METAMODELING FOR POLICY SIMULATIONS WITH MULTIVARIATE OUTCOMES

ZHONG ET AL.

Table S1. List of input variables for the metamodels

Variable Name	Description
sex_male_prev_v2	% of the cohort that is male
age_mon_miu	Mean age of cohort in months (baseline year = 2015)
age_mon_sd	Standard deviation of cohort age in months (baseline year = 2015)
chronic_hcv_v2	Among those who are currently in prison or the prison system, estimated prevalence of chronic HCV infection (RNA+)
idu_status_none	% of individuals who have never been injection drug users
idu_status_former	The percentage of the incarcerated population who report having a history of substance use disorder but no current active use
idu_status_current	The percentage of the incarcerated population who report having a current, active injection drug use disorder
sentence_dur_mon_miu	Mean sentence duration in months
sentence_dur_mon_sd	Standard deviation of sentence duration in months
req_sentdur_eligible	Minimum sentence duration in months to be eligible for HCV treatment
link_care_prison	Of those identified as having chronic HCV infection, the percentage who link to care in prison for HCV disease staging and treatment
prob_link_at_release	Probability of linkage to HCV community care centers when released from prison
cost_test_anti	Cost to the prison or prison system of an HCV antibody test; includes the cost of the test reagents as well as any laboratory, staff, and overhead costs
cost_test_rna	Cost to the prison or prison system of an HCV RNA test; includes the cost of the test reagents as well as any laboratory, staff, and overhead costs

Variable Name	Description
incid_hcv_corr	Monthly incidence of HCV infection in prison for injection drug users
incid_hcv_comm	Monthly incidence of HCV infection in the community for injection drug users
cost_trt_Glec_pib	Monthly cost of treating HCV infection with glecaprevir/pibrentasvir among patients who have never been treated before and who do not have cirrhosis
cost_trt_Sof_vel	Monthly cost of treating HCV infection with sofosbuvir/velpatasvir among patients who have never been treated before and who do have cirrhosis
cost_trt_Sof_vel_vox	Monthly cost for treating HCV infection with sofosbuvir/velpatasvir/voxilaprevir among patients who have previously been treated but did not attain HCV cure and who do not have cirrhosis
cost_trt_Sof_vel_vox_rbv	Monthly cost for treating HCV infection with sofosbuvir/velpatasvir/voxilaprevir/ribavarin among patients who have previously been treated but did not attain hepatitis C cure and who do have cirrhosis
lab_test	Type of fibrosis staging test (APRI [aspartate aminotransferase to platelet ratio] or fibroscan)
test_specif	Specificity of fibrosis staging test (given APRI or fibroscan)